$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Abstract AI-Helper 아이콘AI-Helper

Cisplatin is a member of platinum-containing anti-cancer drugs that causes cross-linking of DNA and ultimately cancer cell apoptosis. The therapeutic function of cisplatin on various types of cancers has been widely reported but the side effects have been discovered together and nephrotoxicity has b...

주제어

AI 본문요약
AI-Helper 아이콘 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

문제 정의

  • In this study, we explored a new biomarker for cisplatin-induced nephrotoxicity. To select proteins that show changes in expression followed by cisplatin treatment, proteomic analysis using 2DE/MALDI-TOF-MS was applied.
본문요약 정보가 도움이 되었나요?

참고문헌 (31)

  1. 1 Damia G. Filiberti L. Vikhanskaya F. Carrassa L. Taya Y. D'Incalci M. Broggini M. Cisplatinum and taxol induce different patterns of p53 phosphorylation Neoplasia (2001) 3 10 16 10.1038/sj.neo.7900122 11326311 

  2. 2 Devarajan P. Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer Ther. (2007) 5 463 470 18449360 

  3. 3 Donzelli E. Carfi M. Miloso M. Strada A. Galbiati S. Bayssas M. Griffon-Etienne G. Cavaletti G. Petruccioli M. G. Tredici G. Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J. Neurooncol. (2004) 67 65 73 10.1023/B:NEON.0000021787.70029.ce 15072449 

  4. 4 Dreier R. Schmid K. W. Gerke V. Riehemann K. Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study. Histochem. Cell Biol. (1998) 110 137 148 10.1007/s004180050275 9720986 

  5. 5 Ea H. K. Monceau V. Camors E. Cohen-Solal M. Charlemagne D. Liote F. Annexin 5 overexpression increased articular chondrocyte apoptosis induced by basic calcium phosphate crystals. Ann. Rheum. Dis. (2008) 67 1617 1625 10.1136/ard.2008.087718 18218665 

  6. 6 Fernandez J. Gharahdaghi F. Mische S. M. Routine identification of proteins from sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels or polyvinyl difluoride membranes using matrix assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS). Electrophoresis (1998) 19 1036 1045 10.1002/elps.1150190619 9638950 

  7. 7 Franke R. M. Kosloske A. M. Lancaster C. S. Filipski K. K. Hu C. Zolk O. Mathijssen R. H. Sparreboom A. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary Nacetyl- beta-D-glucosaminidase Clin. Cancer. Res. (2010) 16 4198 4206 10.1158/1078-0432.CCR-10-0949 20601443 

  8. 8 Hanigan M. H. Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther. (2003) 1 47 61 18185852 

  9. 9 Harmers F. P. Gispen W. H. Neijt J. P. Neurotoxic sideeffects of cisplatin. Eur. J. Cancer (1991) 27 372 376 10.1016/0277-5379(91)90549-S 1827334 

  10. 10 Kenis H. Hofstra L. Reutelingsperger C. P. Annexin A5: shifting from a diagnostic towards a therapeutic realm. Cell. Mol. Life Sci. (2007) 64 2859 2862 10.1007/s00018-007-7297-2 17876516 

  11. 11 Kenis H. van Genderen H. Bennaghmouch A. Rinia H. A. Frederik P. Narula J. Hofstra L. Reutelingsperger C. P. Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry J. Biol. Chem. (2004) 279 52623 52629 10.1074/jbc.M409009200 15381697 

  12. 12 Laurell G. Jungnelius U. High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope (1990) 100 724 734 10.1288/00005537-199007000-00008 2362532 

  13. 13 Lokich J. Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol. (1998) 9 13 21 10.1023/A:1008215213739 9541678 

  14. 14 Markoff A. Gerke V. Expression and functions of annexins in the kidney. Am. J. Physiol. (2005) 289 F949 956 

  15. 15 Matsuda R. Kaneko N. Horikawa Y. Chiwaki F. Shinozaki M. Abe S. Yumura W. Nihei H. Ieiri T. Measurement of urinary annexin V by ELISA and its signifi cance as a new urinarymarker of kidney disease. Clin. Chim. Acta (2000) 298 29 43 10.1016/S0009-8981(00)00218-7 10876002 

  16. 16 Moss S. E. Morgan R. O. The annexins. Genome Biol. (2004) 5 219 10.1186/gb-2004-5-4-219 15059252 

  17. 17 Pepinsky R. B. Tizard R. Mattaliano R. J. Sinclair L. K. Miller G. T. Browning J. L. Chow E. P. Burne C. Huang K. S. Pratt D. Wachter L. Hession C. Frey A. Z. Wallner B. P. Five distinct calcium and phospholipid binding proteins share homology with lipocortin I. J. Biol. Chem. (1988) 263 10799 10811 2968983 

  18. 18 Prestayko A. W. D'Aoust J. C. Issell B. F. Crooke S. T. Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat. Rev. (1979) 6 17 39 10.1016/S0305-7372(79)80057-2 378370 

  19. 19 Quasthoff S. Hartung H. P. Chemotherapy-induced peripheral neuropathy. J. Neurol. (2002) 249 9 17 10.1007/PL00007853 11954874 

  20. 20 Raynal P. Pollard H. B. Annexins: the problem of assessing the biological role for a gene family of multifunctional calciumand phospholipid-binding proteins. Biochim. Biophys. Acta (1994) 1197 63 93 10.1016/0304-4157(94)90019-1 8155692 

  21. 21 Reviakine I. Bergsma-Schutter W. Mazeres-Dubut C. Govorukhina N. Brisson A. Surface topography of the p3 and p6 annexin V crystal forms determined by atomic force microscopy. J. Struct. Biol. (2000) 131 234 239 10.1006/jsbi.2000.4286 11052896 

  22. 22 Sherman S. E. Lippard S. J. Structural aspects of platinum anticancer drug-interactions with DNA. Chem. Rev. (1987) 87 1153 1181 10.1021/cr00081a013 

  23. 23 Siddik Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene (2003) 22 7265 7279 10.1038/sj.onc.1206933 14576837 

  24. 24 Treskes M. van der Vijgh W. J. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother. Pharmacol. (1993) 33 93 106 10.1007/BF00685326 8261581 

  25. 25 Ungethum L. Kenis H. Nicolaes G. A. Autin L. Stoilova-McPhie S. Reutelingsperger C. P. Engineered annexin A5 variants have impaired cell entry for molecular imaging of apoptosis using pretargeting strategies. J. Biol. Chem. (2011) 286 1903 1910 10.1074/jbc.M110.163527 21078669 

  26. 26 van den Eijnde S. M. Luijsterburg A. J. Boshart L. De Zeeuw C. I. van Dierendonck J. H. Reutelingsperger C. P. Vermeij-Keers C. In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure. Cytometry (1997) 29 313 320 10.1002/(SICI)1097-0320(19971201)29:4 3.0.CO;2-A 9415414 

  27. 27 Vermes I. Haanen C. Steffens-Nakken H. Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods (1995) 184 39 51 10.1016/0022-1759(95)00072-I 7622868 

  28. 28 Wang E. J. Snyder R. D. Fielden M. R. Smith R. J. Gu Y. Z. Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology (2008) 246 91 100 10.1016/j.tox.2007.12.031 18289764 

  29. 29 Wang X. Martindale J. L. Holbrook N. J. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. (2000) 275 39435 39443 10.1074/jbc.M004583200 10993883 

  30. 30 Yamashita T. Nagano K. Kanasaki S. Maeda Y. Furuya T. Inoue M. Nabeshi H. Yoshikawa T. Yoshioka Y. Itoh N. Abe Y. Kamada H. Tsutsumi Y. Tsunoda S. Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells. Biochem. Biophys. Res. Commun. (2012) 421 140 144 10.1016/j.bbrc.2012.03.144 22497892 

  31. 31 Yao X. Panichpisal K. Kurtzman N. Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. (2007) 334 115 124 10.1097/MAJ.0b013e31812dfe1e 17700201 

저자의 다른 논문 :

LOADING...

관련 콘텐츠

오픈액세스(OA) 유형

GOLD

오픈액세스 학술지에 출판된 논문

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로